Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian share markets pare gains
Tue, 15 Jul 01:30 pm

Indian share markets pared early gains but continued to trade strong in the post-noon trading session. Majority of the sectoral indices are trading in the green with consumer durable and banking stocks being the biggest gainers. FMCG and pharma are among the few stocks trading in the red.

BSE-Sensex is up 92 points and NSE-Nifty is trading 29 points up. BSE Mid Cap is trading 1.1% up and BSE Small Cap index is trading up by 1.3%. The rupee is trading at 60.11 to the US dollar.

Majority of the domestic pharma stocks are trading in the green with Orchid Chemicals and Indoco Remedies being the major gainers whereas Piramal Enterprises and Dr. Reddy's Lab are trading in the red. As per a leading financial daily, Glenmark Pharmaceuticals has received final approval from the United States Food and Drug Administration (USFDA)for its abbreviated new drug application (ANDA) for Flucinonide Cream USP 0.1%, which is the generic version of Vanos Cream by Medicis. Flucinonide Cream is used to relieve inflammatory manifestations of corticosteroid responsive dermatoses. As per IMS health sales data, Flucinonide cream generated annual sales of USD 103 m in FY14. Glenmark stock is currently trading up by 1.5%.

Food & tobacco stocks are trading mixed. Gains are being led by GSK Consumer, whereas Godfrey Phillips and ITC are the biggest losers. As per a leading business daily, diversified major ITC has indicated investments of Rs 35 bn in the newly created Indian state of Telangana. The company is planning to set up a paper manufacturing unit in the state. The state government which is positive on the move is ready to provide adequate land to the company for establishment of the plant. It may be noted that ITC's major cash cow business of tobacco & cigarette has been bearing the brunt of tax levies. This has led the company to diversify into other businesses to reduce its dependence on tobacco & cigarettes division. As such, the company is also planning to acquire its first 5-star luxury hotel in Goa, one of India's top tourist destination.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian share markets pare gains". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.